Paper Details

  1. Home
  2. Paper Details

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Author: , AgarwalRajiv, AnkerStefan D, BakrisGeorge L, FilippatosGerasimos, JosephAmer, KolkhofPeter, NowackChristina, PittBertram, RossingPeter, RuilopeLuis M, SchloemerPatrick

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article discusses the use of finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, in patients with type 2 diabetes and chronic kidney disease (CKD).
Paper Details　
Original Abstract of the Article :
Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 dia...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2110956

データ提供：米国国立医学図書館（NLM）

Finerenone: A Promising New Treatment for Kidney Disease and Diabetes?

This review explores the potential benefits of Finerenone, a new medication for patients with type 2 diabetes and chronic kidney disease (CKD). Finerenone belongs to a class of drugs known as mineralocorticoid receptor antagonists, which have shown promise in protecting the kidneys and reducing cardiovascular risks in patients with CKD. The review discusses the results of clinical trials investigating the efficacy and safety of Finerenone in this patient population. The authors highlight the potential impact of Finerenone on patient outcomes and the need for further research to fully understand its role in managing CKD and diabetes.

A New Oasis in the Desert of Kidney Disease: Exploring Finerenone

The review suggests that Finerenone could potentially be a valuable new treatment option for patients with type 2 diabetes and CKD. It's like discovering a hidden oasis in the vast desert of kidney disease. The research highlights Finerenone's ability to reduce proteinuria and protect the kidneys in patients with advanced CKD and diabetes. However, the authors emphasize the need for more research to determine its effectiveness in a wider range of CKD stages and to further evaluate its long-term effects.

A Path Forward: Navigating the Complexities of CKD Management

This review is a valuable contribution to the ongoing effort to improve the management of CKD and diabetes. It's like a compass guiding us toward a better understanding of these complex conditions. The review highlights the potential benefits of Finerenone, but it also emphasizes the need for continued research to ensure its safe and effective use in clinical practice. This research is a critical step in our journey toward finding more effective and personalized treatments for patients with CKD and diabetes.

Dr. Camel's Conclusion

This review offers a glimpse into the future of CKD and diabetes management. It's like a camel caravan embarking on a long journey, carrying with it the hopes and dreams of finding a better way to manage these challenging conditions. The potential benefits of Finerenone are exciting, but it's essential to continue researching this medication to ensure its safety and effectiveness for all patients.

Date :
  1. Date Completed 2021-12-23
  2. Date Revised 2022-04-21
Further Info :

Pubmed ID

34449181

DOI: Digital Object Identifier

10.1056/NEJMoa2110956

Related Literature

Article Analysis
・Side Effects of finerenone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.